var data={"title":"Valproate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Valproate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7137?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=valproate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Valproate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=valproate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Valproate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708868\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic failure resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first 6 months of treatment. Serious or fatal hepatotoxicity may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Monitor patients closely for appearance of these symptoms. Perform serum liver tests prior to therapy and at frequent intervals thereafter, especially during the first 6 months.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Children younger than 2 years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When these products are used in this patient group, use with extreme caution and as a sole agent. Weigh the benefits of therapy against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Patients with mitochondrial disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (eg, Alpers-Huttenlocher syndrome). Valproate is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children younger than 2 years who are clinically suspected of having a mitochondrial disorder. In patients older than 2 years who are clinically suspected of having a hereditary mitochondrial disease, only use after other anticonvulsants have failed. Closely monitor this older group of patients during treatment for the development of acute liver injury with regular clinical assessments and serum liver testing. Perform POLG mutation screening in accordance with current clinical practice.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Valproate can cause major congenital malformations, particularly neural tube defects (eg, spina bifida). In addition, valproate can cause decreased IQ scores following in utero exposure. Only use valproate to treat pregnant women with epilepsy if other medications have failed to control their symptoms or are otherwise unacceptable. Do not administer valproate to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a treatment of a spontaneously reversible condition not ordinarily associated with permanent injury or risk of death (eg, migraine). Women should use effective contraception while using valproate.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">An information sheet describing the teratogenic potential of valproate is available for patients.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pancreatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, ordinarily discontinue valproate. Initiate alternative treatment for the underlying medical condition as clinically indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233020\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Depacon;</li>\n      <li>Depakene;</li>\n      <li>Depakote;</li>\n      <li>Depakote ER;</li>\n      <li>Depakote Sprinkles;</li>\n      <li>Stavzor [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233021\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Divalproex;</li>\n      <li>Apo-Valproic;</li>\n      <li>Depakene;</li>\n      <li>Dom-Divalproex;</li>\n      <li>Dom-Valproic Acid;</li>\n      <li>Dom-Valproic Acid E.C.;</li>\n      <li>Epival;</li>\n      <li>Mylan-Divalproex;</li>\n      <li>Mylan-Valproic;</li>\n      <li>Novo-Valproic;</li>\n      <li>PHL-Valproic Acid;</li>\n      <li>PHL-Valproic Acid E.C.;</li>\n      <li>PMS-Divalproex;</li>\n      <li>PMS-Valproic Acid;</li>\n      <li>PMS-Valproic Acid E.C.;</li>\n      <li>ratio-Valproic;</li>\n      <li>Sandoz-Valproic;</li>\n      <li>Teva Divalproex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233068\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous;</li>\n      <li>\n        Antimanic Agent;</li>\n      <li>\n        Histone Deacetylase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233025\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Stavzor has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Seizures:</b> <b>Note:</b> Administer doses &gt;250 mg/day in divided doses. Extended-release formulation is not available in Canada.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Simple and complex absence seizure: Initial: 15 mg/kg/day; increase by 5 to 10 mg/kg/day at weekly intervals until therapeutic levels are achieved; maximum: 60 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Complex partial seizure: Initial: 10 to 15 mg/kg/day; increase by 5 to 10 mg/kg/day at weekly intervals until therapeutic levels are achieved; maximum: 60 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Regular release and delayed release formulations are usually given in 2 to 4 divided doses per day; extended release formulation (Depakote ER) is usually given once daily. In patients previously maintained on regular release valproic acid therapy (Depakene) who convert to delayed release valproate tablets or capsules (Depakote, Stavzor, Epival [Canadian product]), the same daily dose and frequency as the regular release should be used; once therapy is stabilized, the frequency of Depakote, Stavzor, or Epival may be adjusted to 2 to 3 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to Depakote ER from a stable dose of Depakote:</i> May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to monotherapy from adjunctive therapy:</i> The concomitant antiepileptic drug (AED) can be decreased by ~25% every 2 weeks; dosage reduction of the concomitant AED may begin when valproate therapy is initiated or 1 to 2 weeks following valproate initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Total daily IV dose should be equivalent to the total daily dose of the oral valproate product; administer dose as a 60-minute infusion (&le;20 mg/minute) with the same frequency as oral products; switch patient to oral products as soon as possible. Alternatively, rapid infusions of 1.5 to 6 mg/kg/minute have been used in clinical trials to quickly achieve therapeutic concentrations, and were generally well tolerated (Ramsay 2003; Venkataraman 1999; Wheless 2004). One study reported undiluted valproic acid administered at &le;10 mg/kg/minute (dose of &le;30 mg/kg) was well tolerated (Limdi 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mania:</b> Oral: <b>Note:</b> Extended-release formulation is not available in Canada.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depakote tablet, Stavzor, Epival [Canadian product]:</i> Initial: 750 mg/day in divided doses; dose should be adjusted as rapidly as possible to desired clinical effect; maximum recommended dosage: 60 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depakote ER:</i> Initial: 25 mg/kg/day given once daily; dose should be adjusted as rapidly as possible to desired clinical effect; maximum recommended dose: 60 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine prophylaxis: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depakote tablet, Stavzor:</i> 250 mg twice daily; adjust dose based on patient response, up to 1,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depakote ER:</i> 500 mg once daily for 7 days, then increase to 1,000 mg once daily; adjust dose based on patient response; usual dosage range: 500 to 1,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Painful diabetic neuropathy (off-label use):</b> Oral: Initial: 500 mg/day; increase to 1,000 mg/day after 1 week; doses as high as 1,200 mg/day have been studied (Kochar 2002; Kochar 2004). Additional data may be necessary to further define the role of valproate in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia (off-label use):</b> Oral: Usual dose: 1,000 mg daily (Kochar 2005). Additional data may be necessary to further define the role of valproate in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus (off-label use):</b> IV: Loading dose: 20 to 40 mg/kg administered at rate of 3 to 6 mg/kg/minute; if necessary, may give an additional dose of 20 mg/kg 10 minutes after the loading infusion (NCS [Brophy 2012]) <b>or </b>40 mg/kg as a single dose (maximum dose: 3,000 mg) (AES [Glauser 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traumatic brain injury related agitation and aggression (off-label use):</b> Oral: Usual dosage range: 1,250 to 1,800 mg/day; adjust dose based on patient response; doses as high as 3,500 mg/day have been reported (Chatham Showalter 2000; Kim 2002). Additional data may be necessary to further define the role of valproate in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233045\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=valproate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Valproate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Stavzor has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Seizures:</b> <b>Note:</b> Administer doses &gt;250 mg daily in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Simple and complex absence seizures:</i> Refer to adult dosing. Larger maintenance doses may be required in younger children.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Complex partial seizures: </i> Children &ge;10 years: Refer to adult dosing. Larger maintenance doses may be required in younger children.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Depakote ER is not recommended for use in children &lt;10 years of age. Extended-release formulation is not available in Canada.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to Depakote ER from a stable dose of Depakote:</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to monotherapy from adjunctive therapy:</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal (off-label route): Dilute syrup 1:1 with water for use as a retention enema; acute and maintenance dose: 6 to 15 mg/kg/dose (Graves, 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine prophylaxis:</b> Children &ge;12 years and Adolescents (Stavzor): Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus (off-label use):</b> Infants, Children, and Adolescents: IV: 20 to 40 mg/kg administered at rate of 1.5 to 3 mg/kg/minute; if necessary, may give an additional dose of 20 mg/kg 10 minutes after the loading infusion (NCS [Brophy, 2012]) <b>or</b> 40 mg/kg as a single dose (maximum dose: 3,000 mg) (AES [Glauser 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233026\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Oral, IV: Lower initial doses are recommended due to decreased elimination and increased incidences of somnolence in the elderly; no specific dosage recommendations are provided by the manufacturer. Upward titration should be done slowly and with close monitoring for adverse events (eg, sedation, dehydration, decreased nutritional intake). Safety and efficacy for use in patients &gt;65 years have not been studied for migraine prophylaxis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233027\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to severe impairment: No dosage adjustment necessary; however, due to decreased protein binding in renal impairment, monitoring of free valproate concentrations may be of clinical value. Total valproate concentrations may be misleading.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: No dosage adjustment necessary; however, due to decreased protein binding in renal impairment, monitoring of free valproate concentrations may be of clinical value. Total valproate concentrations may be misleading. Dose supplementation is generally not needed, but may be required with high-flux dialyzers (Asconap&eacute; 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233028\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild to moderate impairment: Not recommended for use in hepatic disease; clearance is decreased with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction. Free concentrations of valproate may be elevated while total concentrations appear normal, therefore, monitoring only total valproate concentrations may be misleading.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232991\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stavzor: 125 mg [DSC], 250 mg [DSC], 500 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release Sprinkle, Oral, as divalproex sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote Sprinkles: 125 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as valproate sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depacon: 100 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as valproate sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as valproate sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene: 250 mg/5 mL (480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (5 mL, 10 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as divalproex sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote: 125 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote: 250 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote: 500 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as divalproex sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote ER: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232975\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22782778\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strengths of divalproex sodium and valproate sodium products are expressed in terms of valproic acid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49367109\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Enteric-coated, Oral, as divalproex sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epival: 125 mg, 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49367104\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Stavzor has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16335927\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakene, Depakote, Depakote ER: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060,019680s047lbl.pdf#page=97&amp;token=gUxbz1UN2BSgaiRLjpoLwmokJIz/EbBX7qsoVvB4wjSI7DzGpZXpmEyGrk6NX6NvxB36wK0jmMnTTiMX1OcwgqQ1MUTjeHgzXPOpQFS1ZrZF8dNGl8JWKEFrG3LXbPKR&amp;TOPIC_ID=10035\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060,019680s047lbl.pdf#page=97</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stavzor: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WjFwRaG4FaLSZzydQSVIIFw==&amp;TOPIC_ID=10035\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232995\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Oral valproate products may cause GI upset; taking with food or slowly increasing the dose may decrease GI upset should it occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakote ER: Swallow whole; do not crush or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakote Sprinkle capsules may be swallowed whole or capsule opened and sprinkled on small amount (1 teaspoonful) of soft food (eg, pudding, applesauce) to be used immediately (do not store or chew).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakene capsule, Stavzor: Swallow whole; do not chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epival [Canadian product]: Swallow tablet whole; do not chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Following dilution to final concentration, manufacturer's labeling recommends administering over 60 minutes at a rate &le;20 mg/minute. Alternatively, more rapid infusion rates of 1.5-6 mg/kg/minute have been used in clinical trials to quickly achieve therapeutic concentrations, and were generally well tolerated (Ramsay, 2003; Wheless, 2004). One study reported undiluted valproic acid administered at &le;10 mg/kg/minute (dose of &le;30 mg/kg) was well tolerated (Limdi, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations for status epilepticus</i> (NCS [Brophy, 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Maximum administration rate of 3 to 6 mg/kg/minute for the loading dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Maximum administration rate of 1.5 to 3 mg/kg/minute for the loading dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133423\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232994\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epilepsy: </b>Oral, IV: Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures; monotherapy and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mania:</b> Depakote, Depakote ER, Stavzor, Epival [Canadian product]: Mania associated with bipolar disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine: </b>Depakote, Depakote ER, Stavzor: Migraine prophylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitation of use: Do not administer to a woman of childbearing potential unless essential for the management of her condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25497638\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Painful diabetic neuropathy; Postherpetic neuralgia; Status epilepticus (adults); Status epilepticus (infants/children/adolescents); Traumatic brain injury-related agitation and aggression; Traumatic brain injury-related seizure prophylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233076\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene may be confused with Depakote </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote may be confused with Depakene, Depakote ER, Senokot</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote ER may be confused with divalproex enteric coated</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valproate sodium may be confused with vecuronium</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232982\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported with oral administration, unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (oral: 31%; intravenous: 3% to 4%), drowsiness (oral: 7% to 30%; intravenous: 2% to 11%), dizziness (oral: 12% to 25%; intravenous: 5% to 7%), insomnia (&gt;1% to 15%), pain (oral: 11%; intravenous: 1%), nervousness (oral: 7% to 11%; intravenous: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (&gt;1% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (oral: 15% to 48%; intravenous: 3% to 6%), vomiting (oral: 7% to 27%; intravenous: 1%), abdominal pain (oral: 7% to 23%; intravenous: 1%), diarrhea (oral: 7% to 23%; intravenous: &lt;1%), dyspepsia (7% to 23%), anorexia (&gt;1% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (1% to 27%; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (&le;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (&le;57%), weakness (6% to 27%; intravenous: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Diplopia (&gt;1% to 16%), visual disturbance (amblyopia, blurred vision &le;1% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (&gt;1% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (&gt;1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (&gt;1% to 8%), edema (&gt;1% to 5%), facial edema (&gt;1% to 5%), hypertension (&gt;1% to 5%), hypotension (1% to 5%), orthostatic hypotension (1% to 5%), palpitations (&gt;1% to 5%), vasodilatation (oral: &gt;1% to 5%; intravenous: &lt;1%), tachycardia (&gt;1% to &lt;5%), chest pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Ataxia (&gt;1% to 8%), amnesia (&gt;1% to 7%), paresthesia (&le;7%), abnormality in thinking (&gt;1% to 6%), emotional lability (&gt;1% to 6%), abnormal dreams (&gt;1% to 5%), abnormal gait (&gt;1% to 5%), confusion (&gt;1% to 5%), depression (&gt;1% to 5%), hallucination (&gt;1% to 5%), hypertonia (&gt;1% to 5%), speech disturbance (&gt;1% to 5%), tardive dyskinesia (&gt;1% to 5%), agitation (1% to 5%), catatonia (1% to 5%), chills (1% to 5%), hyper-reflexia (1% to 5%), vertigo (1% to 5%), anxiety (&gt;1% to &lt;5%), malaise (&gt;1% to &lt;5%), myasthenia (&gt;1% to &lt;5%), personality disorder (&gt;1% to &lt;5%), twitching (&gt;1% to &lt;5%), sleep disorder (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&gt;1% to 6%), maculopapular rash (&gt;1% to 5%), pruritus (&gt;1% to 5%), xeroderma (&gt;1% to 5%), diaphoresis (oral: &gt;1%; intravenous: &lt;1%), erythema nodosum (&gt;1%), vesiculobullous dermatitis (&gt;1%), furunculosis (1% to 5%), seborrhea (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (&gt;1% to 9%), weight loss (6%), amenorrhea (&gt;1% to &lt;5%), menstrual disease (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Increased appetite (&gt;1% to 6%), constipation (&gt;1% to 5%), flatulence (&gt;1% to 5%), periodontal abscess (&gt;1% to 5%), fecal incontinence (1% to 5%), gastroenteritis (1% to 5%), glossitis (1% to 5%), stomatitis (1% to 5%), xerostomia (1% to 5%), eructation (&gt;1% to &lt;5%), hematemesis (&gt;1% to &lt;5%), pancreatitis (&gt;1% to &lt;5%), dysgeusia (2%), dysphagia (&gt;1%), gingival hemorrhage (&gt;1%), hiccups (&gt;1%), oral mucosa ulcer (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Cystitis (&gt;1% to 5%), dysmenorrhea (&gt;1% to 5%), dysuria (&gt;1% to 5%), urinary incontinence (&gt;1% to 5%), vaginal hemorrhage (&gt;1% to 5%), urinary frequency (&gt;1% to &lt;5%), vaginitis (&gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Ecchymoses (&gt;1% to 5%), petechia (&gt;1% to &lt;5%), hypoproteinemia (&gt;1%), prolonged bleeding time (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&gt;1% to &lt;5%), increased serum AST (&gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (&gt;1% to 5%), fungal infection (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (intravenous: 3%), injection site reaction (intravenous: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&gt;1% to 8%), arthralgia (&gt;1% to 5%), discoid lupus erythematosus (&gt;1% to 5%), leg cramps (&gt;1% to 5%), hypokinesia (1% to 5%), neck pain (1% to 5%), neck stiffness (1% to 5%), osteoarthritis (1% to 5%), dysarthria (&gt;1% to &lt;5%), myalgia (&gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Nystagmus (1% to 8%), conjunctivitis (1% to 5%), dry eye syndrome (1% to 5%), eye pain (1% to 5%), photophobia (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (1% to 7%), deafness (&gt;1% to 5%), otitis media (&gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (oral: 2% to 8%; intravenous: &lt;1%), bronchitis (5%), rhinitis (&gt;1% to 5%), dyspnea (1% to 5%), cough (&gt;1% to &lt;5%), epistaxis (&gt;1% to &lt;5%), pneumonia (&gt;1% to &lt;5%), sinusitis (&gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&gt;1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal behavior, abnormal thyroid function tests, acute porphyria, aggressive behavior, agranulocytosis, anaphylaxis, anemia, aplastic anemia, asthenospermia, azoospermia, bone fracture, bone marrow depression, bradycardia, brain disease (rare), breast hypertrophy, cerebral atrophy (reversible or irreversible), change in prothrombin time, changes of hair (color, texture), coma (rare), decreased bone mineral density, decreased plasma carnitine concentrations, decreased platelet aggregation, decreased spermatozoa motility, dementia, developmental delay (learning disorder), disturbance in attention, DRESS syndrome, drug-induced Parkinson disease, emotional disturbance, eosinophilia, erythema multiforme, euphoria, Fanconi-like syndrome (rare, in children), galactorrhea, hemorrhage, hepatic failure, hepatotoxicity, hirsutism, hostility, hyperactivity, hyperammonemia, hyperammonemic encephalopathy (in patients with UCD), hyperandrogenism, hyperglycinemia, hypersensitivity angiitis, hypersensitivity reaction, hypoesthesia, hypofibrinogenemia, hyponatremia, hypothermia, increased testosterone level, injection site inflammation, leukopenia, lymphocytosis, macrocytosis, male infertility, myelodysplasia, nail bed changes, nail disease, oligospermia, ostealgia, osteopenia, osteoporosis, pancytopenia, parotid gland enlargement, polycystic ovary syndrome (rare), psychomotor disturbance, psychosis, seizure (paradoxical), severe hypersensitivity (with multiorgan dysfunction), SIADH, skin photosensitivity, sleep disorder, spermatozoa disorder (abnormal morphology), Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, toxic epidermal necrolysis (rare), urinary incontinence, urinary tract infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232998\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to valproic acid, divalproex, derivatives, or any component of the formulation; hepatic disease or significant impairment; urea cycle disorders; pregnant women for the prevention of migraine; known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg, Alpers-Huttenlocher syndrome [AHS]) or children &lt;2 years of age suspected of having a POLG-related disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Known porphyria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232979\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood disorders: May cause dose-related thrombocytopenia, inhibition of platelet aggregation, and bleeding. In some cases, platelet counts may be normalized with continued treatment; however, reduce dose or discontinue drug if patient develops evidence of hemorrhage, bruising, or a disorder of hemostasis/coagulation. Evaluate platelet counts prior to initiating therapy and periodically thereafter. Probability of thrombocytopenia increases with total valproate levels &ge;110 mcg/mL in females or &ge;135 mcg/mL in males. In addition to platelets, valproate may be associated with a decrease in other cell lines and myelodysplasia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Brain atrophy: Reversible and irreversible cerebral and cerebellar atrophy have been reported; motor and cognitive function should be routinely monitored to assess for signs and symptoms of brain atrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic failure: <b>[US Boxed Warning]: Hepatic failure resulting in fatalities has occurred in patients, usually in the initial 6 months of therapy; children &lt;2 years of age are at considerable risk. Risk is also increased in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (eg, Alpers-Huttenlocher syndrome [AHS]). </b> Other risk factors include organic brain disease, mental retardation with severe seizure disorders, congenital metabolic disorders, and patients on multiple anticonvulsants. Monitor patients closely for appearance of malaise, weakness, facial edema, anorexia, jaundice, and vomiting; discontinue immediately with signs/symptom of significant or suspected impairment. Liver function tests should be performed at baseline and at regular intervals after initiation of therapy, especially within the first 6 months. Hepatic dysfunction may progress despite discontinuing treatment. Should only be used as monotherapy and with extreme caution in children &lt;2 years of age and/or patients at high risk for hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperammonemia/encephalopathy: Hyperammonemia and/or encephalopathy, sometimes fatal, has been reported following the initiation of valproate therapy and may be present with normal transaminase levels. Ammonia levels should be measured in patients who develop unexplained lethargy and vomiting, or changes in mental status or in patients who present with hypothermia. Discontinue therapy if ammonia levels are increased and evaluate for possible urea cycle disorder (UCD). Hyperammonemic encephalopathy has been reported in patients with UCD, particularly ornithine transcarbamylase deficiency. Use is contraindicated in patients with known UCD. Evaluation of UCD should be considered for the following patients prior to the start of therapy: History of unexplained encephalopathy or coma; encephalopathy associated with protein load; pregnancy or postpartum encephalopathy; unexplained mental retardation; history of elevated plasma ammonia or glutamine; history of cyclical vomiting and lethargy; episodic extreme irritability, ataxia; low BUN or protein avoidance; family history of UCD or unexplained infant deaths (particularly male); or signs or symptoms of UCD (hyperammonemia, encephalopathy, respiratory alkalosis). Hyperammonemia and/or encephalopathy may also occur with concomitant topiramate therapy in patients who previously tolerated monotherapy with either medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothermia: Hypothermia (unintentional drop in core body temperature to &lt;35&deg;C/95&deg;F) has been reported with valproate therapy; hypothermia may or may not be associated with hyperammonemia; may also occur with concomitant topiramate therapy following topiramate initiation or dosage increase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity reactions (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious, sometimes fatal multiorgan hypersensitivity reactions have rarely been reported with some antiepileptic drugs including valproate therapy in adults and children; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: <b>[US Boxed Warning]: Cases of life-threatening pancreatitis, occurring at the start of therapy or following years of use, have been reported in adults and children.</b> Some cases have been hemorrhagic with rapid progression of initial symptoms to death. Promptly evaluate symptoms of abdominal pain, nausea, vomiting, and/or anorexia; should generally be discontinued if pancreatitis is diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute head trauma: Not recommended for post-traumatic seizure prophylaxis in patients with acute head trauma; study results for this indication suggested increased mortality with IV valproate use compared to IV phenytoin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Contraindicated with significant impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mitochondrial disease: <b>[US Boxed Warning]: Risk of valproate-induced acute liver failure and death is increased in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial polymerase gamma (POLG) gene (eg, Alpers Huttenlocher syndrome [AHS]). Use is contraindicated in patients with known mitochondrial disorders caused by POLG mutations and children &lt;2 years of age suspected of having a POLG-related disorder. Use in children &ge;2 years of age suspected of having a POLG-related disorder only after other anticonvulsants have failed and with close monitoring for the development of acute liver injury.</b> POLG mutation testing should be performed in accordance with current clinical practice.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution as elderly patients may be more sensitive to sedating effects and dehydration; in some elderly patients with somnolence, concomitant decreases in nutritional intake and weight loss were observed. Reduce initial dosages in elderly and closely monitor fluid status, nutritional intake, somnolence, and other adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children &lt;2 years of age are at increased risk for fatal hepatotoxicity; if valproate therapy is used in this age group, use with extreme caution and only as monotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: May cause major congenital malformations such as neural tube defects (eg, spina bifida) and decreased IQ scores following in utero exposure. Use is contraindicated in pregnant women for the prevention of migraine. Use is not recommended in women of childbearing potential for any other condition unless valproate is essential to manage her condition and alternative therapies are not appropriate. Effective contraception should be used during therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal: Medication residue in stool has been reported (rarely) with oral Depakote (divalproex sodium) formulations; some reports have occurred in patients with shortened GI transit times (eg, diarrhea) or anatomic GI disorders (eg, ileostomy, colostomy). In patients reporting medication residue in stool, it is recommended to monitor valproate level and clinical condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Viral replication: <i>In vitro</i> studies have suggested valproate stimulates the replication of HIV and CMV viruses under experimental conditions. The clinical consequence of this is unknown, but should be considered when monitoring affected patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233062\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak); <b>Induces</b> CYP2A6 (weak/moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15578418\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10035&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amdinocillin: Valproate Products may enhance the adverse/toxic effect of Amdinocillin. Specifically, the risk for carnitine deficiency may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Valproate Products may increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Valproate Products may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbapenems: May decrease the serum concentration of Valproate Products. Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproMAZINE: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the serum concentration of Valproic Acid and Derivatives. Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cosyntropin: May enhance the hepatotoxic effect of Valproate Products. Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: May decrease the serum concentration of Valproate Products. Valproate Products may increase the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May increase the serum concentration of Valproate Products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations.  Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fotemustine: Valproate Products may enhance the adverse/toxic effect of Fotemustine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Valproate Products may enhance the adverse/toxic effect of LamoTRIgine. Valproate Products may increase the serum concentration of LamoTRIgine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: Valproate Products may increase the serum concentration of Lesinurad. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LORazepam: Valproate Products may increase the serum concentration of LORazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Systemic): Valproate Products may increase the serum concentration of Minoxidil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: Valproate Products may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: Valproate Products may decrease the serum concentration of OXcarbazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: Valproate Products may increase the serum concentration of Paliperidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Valproate Products may decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, may be decreased. Primidone may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: Valproate Products may enhance the therapeutic effect of Propofol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Valproate Products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RisperiDONE: Valproate Products may enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: Valproate Products may increase the serum concentration of Rufinamide.  Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Valproate Products may increase the serum concentration of Sodium Oxybate.  Management: Consider a sodium oxybate dose reduction of at least 20% if combined with valproic acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temozolomide: Valproate Products may enhance the adverse/toxic effect of Temozolomide. Valproate Products may increase the serum concentration of Temozolomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May enhance the adverse/toxic effect of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Valproate Products may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Valproate Products may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorinostat: Valproate Products may enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Valproate Products may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233015\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Food may delay but does not affect the extent of absorption. Management: May administer with food if GI upset occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232987\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (migraine prophylaxis)/D (all other indications) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233002\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies and in human pregnancies. <b>[US Boxed Warning]: May cause major congenital malformations, such as neural tube defects (eg, spina bifida) and decreased IQ scores following in utero exposure. Use is contraindicated in pregnant women for the prevention of migraine. Use is not recommended in women of childbearing potential for any other condition unless valproate is essential to manage her condition and alternative therapies are not appropriate. Effective contraception should be used during therapy. </b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Valproic acid crosses the placenta (Harden 2009b). Neural tube defects, craniofacial defects, cardiovascular malformations, hypospadias, and limb malformations have been reported. Information from the North American Antiepileptic Drug Pregnancy Registry notes the rate of major malformations to be 9% to 11% following an average exposure to valproate monotherapy 1,000 mg/day; this is an increase in congenital malformations when compared with monotherapy with other antiepileptic drugs (AED). Based on data from the CDC National Birth Defects Prevention Network, the risk of spinal bifida is approximately 1% to 2% following valproate exposure (general population risk estimated to be 0.06% to 0.07%).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Nonteratogenic adverse effects have also been reported. Decreased IQ scores have been noted in children exposed to valproate in utero when compared to children exposed to other antiepileptic medications or no antiepileptic medications; the risk of autism spectrum disorders may also be increased. Fatal hepatic failure and hypoglycemia in infants have been noted in case reports following in utero exposure to valproic acid.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Clotting factor abnormalities (hypofibrinogenemia, thrombocytopenia, or decrease in other coagulation factors) may develop in the mother following valproate use during pregnancy; close monitoring of coagulation factors is recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines recommend complete avoidance of valproic acid and derivatives for the treatment of epilepsy in pregnant women whenever possible (Harden 2009a), especially when used for conditions not associated with permanent injury or risk of death. Effective contraception should be used during treatment. When pregnancy is being planned, consider tapering off of therapy prior to conception if appropriate; abrupt discontinuation of therapy may cause status epilepticus and lead to maternal and fetal hypoxia. Folic acid decreases the risk of neural tube defects in the general population; supplementation with folic acid should be used prior to conception and during pregnancy in all women, including those taking valproate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry is available for women who have been exposed to valproic acid. Patients may enroll themselves in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233003\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Valproate is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of valproic acid is 2.7% to 5.4% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 20 to 40 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of valproic acid was calculated using a milk concentration of 50 mmol/L (7.2 mg/L), providing an estimated daily infant dose via breast milk of 1.08 mg/kd/day. This milk concentration represents the mean milk concentration at postpartum day 5 following maternal administration of soldium valproate 1,600 mg/day throughout pregnancy and the immediate postpartum period in one woman (Alexander 1979). Valproic acid can be detected in the plasma of breastfed infants (Hagg 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The risk of valproic acid-related hepatotoxicity is increased following therapeutic use in pediatric patients &lt;2 years of age; theoretically, this risk is also present in infants exposed to valproic acid via breast milk. Reported adverse effects in breastfed infants include a possible case of thrombocytopenic purpura, anemia, and reticulocytosis (Stahl 1997).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommends that caution be used if valproic acid is administered to breastfeeding women. The World Health Organization (WHO) states that valproic acid is compatible with breastfeeding; monitoring of the infant for side effects (eg, jaundice) is recommended (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232989\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver enzymes (at baseline and frequently during therapy especially during the first 6 months), CBC with platelets (baseline and periodic intervals), PT/PTT (especially prior to surgery), serum ammonia (with symptoms of lethargy, mental status change), serum valproate levels; suicidality (eg, suicidal thoughts, depression, behavioral changes); motor and cognitive function (for signs or symptoms of brain atrophy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232992\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In general, trough concentrations should be used to assess adequacy of therapy; peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). Within 2 to 4 days of initiation or dose adjustment, trough concentrations should be drawn just before the next dose (extended-release preparations) or before the morning dose (for immediate-release preparations). Patients with epilepsy should not delay taking their dose for &gt;2 to 3 hours. Additional patient-specific factors must be taken into consideration when interpreting drug levels, including indication, age, clinical response, pregnancy status, adherence, comorbidities, adverse effects, and concomitant medications (Patsalos, 2008; Reed, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproic acid, total:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Therapeutic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Epilepsy: 50 to 100 mcg/mL (SI: 350 to 700 micromole/L); although seizure control may improve at levels &gt;100 mcg/mL (SI: 700 micromole/L), toxicity may occur at levels of 100 to 150 mcg/mL (SI: 700 to 1,040 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mania: 50 to 125 mcg/mL (SI: 350 to 875 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic: Despite the usual upper reference range of 100 to 125 mcg/mL, clinical toxicity can occur at lower concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epilepsy: Although seizure control may improve at levels &gt;100 mcg/mL (SI: 700 micromole/L), toxicity may occur at levels of 100 to 150 mcg/mL (SI: 700 to 1,050 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mania: Clinical response seen with trough levels between 50 to 125 mcg/mL (SI: 350 to 875 micromole/L); risk of toxicity increases at levels &gt;125 mcg/mL (SI: 875 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproic acid, free:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Therapeutic: 5 to 15 mcg/mL (Smetana 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232978\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Causes increased availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, to brain neurons or may enhance the action of GABA or mimic its action at postsynaptic receptor sites. Divalproex sodium is a compound of sodium valproate and valproic acid; divalproex dissociates to valproate in the GI tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232997\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes into CSF at concentrations similar to unbound concentration in plasma (ie, ~10% of total plasma concentration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: Total valproate: 11 L/1.73 m<sup>2</sup>; Free valproate 92 L/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding (concentration dependent): 80% to 90%; free fraction: ~10% at 40 mcg/mL and ~18.5% at 130 mcg/mL; protein binding decreased in neonates, the elderly and patients with hepatic or renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via glucuronide conjugation (30% to 50% of administered dose) and 40% via mitochondrial beta-oxidation; other oxidative metabolic pathways occur to a lesser extent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Depakote ER: ~90% relative to IV dose and ~89% relative to delayed release formulation. In pediatric patients 10 to 17 years of age, once-daily administration of Depakote-ER produced valproate plasma concentration-time profiles similar to adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (increased in neonates, elderly, and patients with liver impairment):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newborns (exposed to VPA in utero): 30 to 60 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates first week of life: 40 to 45 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &lt;10 days: 10 to 67 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;2 months: 7 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 2 to 14 years: 9 hours (range: 3.5 to 20 hours) (Cloyd 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 9 to 19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Depakote tablet and sprinkle capsules: ~4 hours; Depakote ER: 4 to 17 hours; Stavzor: 2 hours; Epival [Canadian product]: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal (off-label route): 1 to 3 hours (Graves 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (30% to 50% as glucuronide conjugate, &lt;3% as unchanged drug); faster clearance in children who receive other antiepileptic drugs and those who are younger; age and polytherapy explain 80% of interpatient variability in total clearance; children &gt;10 years of age have pharmacokinetic parameters similar to adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> ER tablets have 10% to 20% less fluctuation in serum concentration than delayed-release tablets. ER tablets are not bioequivalent to delayed-release tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570489\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Stavzor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $153.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $301.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $555.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Depakote Sprinkles Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $137.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Divalproex Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $89.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Depakene Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $404.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Valproic Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $82.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Depacon Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $25.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Valproate Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $8.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Depakene Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (480 mL): $413.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Depakote ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $257.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $453.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Divalproex Sodium ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $167.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $295.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Depakote Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $144.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $283.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $522.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Divalproex Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $89.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $176.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $324.97</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233005\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Absenor (SE);</li>\n      <li>Aleptiz (PH);</li>\n      <li>Apilepsin (HR);</li>\n      <li>Convulex (AT, BE, BG, CH, CZ, DE, EE, GB, HN, HU, IE, LU, PL, RU, SG, TR, TW);</li>\n      <li>Delepsine (DK);</li>\n      <li>Depacon (KP, PH);</li>\n      <li>Depakene (AR, CN, CO, ID, JP, PE, PH, PY, UY);</li>\n      <li>Depakin (IT, PK, RU, TR);</li>\n      <li>Depakine (AE, AT, BE, BG, BH, CH, CY, EE, EG, ES, FR, GR, HN, HU, IQ, IR, JO, KW, LB, LU, LY, OM, PL, PT, QA, RU, SA, SY, TH, VE, YE);</li>\n      <li>Depakine Chrono (KP, LU, TH, TW);</li>\n      <li>Depakote (BZ, SR);</li>\n      <li>Deprakine (DK, FI, NO);</li>\n      <li>Desorate (TH);</li>\n      <li>Epilim (AU, BF, BJ, CI, ET, GB, GH, GM, GN, HK, IE, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, NZ, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Epilim Chrono 500 (BB, BM, BS, GY, HK, JM, MY, NL, PR, TT);</li>\n      <li>Episenta (GB);</li>\n      <li>Epival (AE, BH, CR, CY, DO, EG, GT, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PH, QA, SA, SV, SY, YE);</li>\n      <li>Ergenyl (SE);</li>\n      <li>Everiden (HU);</li>\n      <li>Lepavent (TW);</li>\n      <li>Leptilan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Neuractin (CO);</li>\n      <li>Oltril (TH);</li>\n      <li>Orfiril (CZ, DE, FI, HU);</li>\n      <li>Orfiril Retard (SG);</li>\n      <li>Petilin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Valcote (CO, EC);</li>\n      <li>Valeptol SR (KP);</li>\n      <li>Valpakine (BR, EC);</li>\n      <li>Valparin (TH);</li>\n      <li>Valporal (IL);</li>\n      <li>Valprax (PE);</li>\n      <li>Valpro (AU, HK);</li>\n      <li>Valpron (VE);</li>\n      <li>Valsup (CO);</li>\n      <li>Valtec-CR (IN);</li>\n      <li>Vematina (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17616473\"></a>Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. <i>Seizure</i>. 2007;16(6):527-532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/17616473/pubmed\" target=\"_blank\" id=\"17616473\">17616473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"373647\"></a>Alexander FW. Sodium valproate and pregnancy. <i>Arch Dis Child</i>. 1979;54(3):240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/373647/pubmed\" target=\"_blank\" id=\"373647\">373647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21480881\"></a>Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. <i>Epilepsia</i>. 2011;52(7):1292&ndash;1296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/21480881/pubmed\" target=\"_blank\" id=\"21480881\">21480881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asconap&eacute; JJ. Use of antiepileptic drugs in hepatic and renal disease. <i>Handb Clin Neurol</i>. 2014;119:417-432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/24365310/pubmed\" target=\"_blank\" id=\"24365310\">24365310</a>]</span><span class=\"doi\">10.1016/B978-0-7020-4086-3.00027-8</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20402746\"></a>Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. <i>Eur J Neurol</i>. 2010;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/20402746/pubmed\" target=\"_blank\" id=\"20402746\">20402746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17511552\"></a>Bratton SL, Chestnut RM, Ghajar J, et al; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS. Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. <i>J Neurotrauma</i>. 2007;24 Suppl 1:S83-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/17511552/pubmed\" target=\"_blank\" id=\"17511552\">17511552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in <i>Neurology</i>. 2011;77(6):603]. <i>Neurology</i>. 2011;76(20):1758-1765.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10956575\"></a>Chatham Showalter PE, Kimmel DN. Agitated symptom response to divalproex following acute brain injury. <i>J Neuropsychiatry Clin Neurosci.</i> 2000,12(3):395-397.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10956575/pubmed\" target=\"_blank\" id=\"10956575\">10956575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloyd JC, Fischer JH, Kriel RL, et al, &ldquo;Valproic Acid Pharmacokinetics in Children. IV. Effects of Age and Antiepileptic Drugs on Protein Binding and Intrinsic Clearance,&rdquo; Clin Pharmacol Ther, 1993, 53(1):22-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/8422737/pubmed\" target=\"_blank\" id=\"8422737\">8422737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depacon (valproate sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depacon (valproate sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depacon (valproate sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakene (valproic acid) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakene (valproic acid) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakene (valproic acid) [prescribing information]. North Chicago, IL: AbbVie Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote Delayed-Release Tablets [prescribing information]. North Chicago, IL: AbbVie Inc; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote ER (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote ER (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote ER (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Depakote (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depakote Sprinkle Capsules (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10690983\"></a>Dikmen SS, Machamer JE, Winn HR, Anderson GD, Temkin NR. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. <i>Neurology</i>. 2000;54(4):895-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10690983/pubmed\" target=\"_blank\" id=\"10690983\">10690983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epival (divalproex sodium) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaitanis JN and Drislane FW, &ldquo;Status Epilepticus: A Review of Different Syndromes, Their Current Evaluation, and Treatment,&rdquo; <i>Neurologist</i>, 2003, 9(2):61-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/12808369/pubmed\" target=\"_blank\" id=\"12808369\">12808369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18798830\"></a>Gilad R, Izkovitz N, Dabby R, et al, Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. <i>Acta Neurol Scand</i>. 2008;118(5):296-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/18798830/pubmed\" target=\"_blank\" id=\"18798830\">18798830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26900382\"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/26900382/pubmed\" target=\"_blank\" id=\"26900382\">26900382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graves NM and Kriel RL, &ldquo;Rectal Administration of Antiepileptic Drugs in Children,&quot; <i>Pediatr Neurol</i>, 1987, 3(6):321-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/3334021/pubmed\" target=\"_blank\" id=\"3334021\">3334021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hagg S and Spigset O, &ldquo;Anticonvulsant Use During Lactation,&rdquo; <i>Drug Saf </i>, 2000, 22(6):425-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10877037/pubmed\" target=\"_blank\" id=\"10877037\">10877037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al, &quot;Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009a, 73(2):133-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Pennell PB, Koppel BS, et al, &quot;Practice Parameter Update Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Vitamin K, Folic Acid, Blood Levels, and Breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009b, 73(2):142-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/19398680/pubmed\" target=\"_blank\" id=\"19398680\">19398680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hodges BM and Mazur JE, &ldquo;Intravenous Valproate in Status Epilepticus,&rdquo; <i>Ann Pharmacother</i>, 2001, 35(11):1465-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/11724100/pubmed\" target=\"_blank\" id=\"11724100\">11724100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11983796\"></a>Kim E, Humaran TJ. Divalproex in the management of neuropsychiatric complications of remote acquired brain injury. <i>J Neuropsychiatry Clin Neurosci</i>. 2002;14(2):202-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/11983796/pubmed\" target=\"_blank\" id=\"11983796\">11983796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12371916\"></a>Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. <i>Acta Neurol Scand,</i> 2002;106(5):248-252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/12371916/pubmed\" target=\"_blank\" id=\"12371916\">12371916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14702509\"></a>Kochar DK, Rawat N, Agrawal RP, Vyas A, Beniwal R, Kochar SK, Garg P. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. <i>QJM.</i> 2004;97(1):33-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/14702509/pubmed\" target=\"_blank\" id=\"14702509\">14702509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15625351\"></a>Kochar DK, Garg P, Bumb RA, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. <i>QJM</i>. 2005;98(1):29-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/15625351/pubmed\" target=\"_blank\" id=\"15625351\">15625351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leao M, &ldquo;Valproate as a Cause of Hyperammonemia in Heterozygotes With Ornithine-Transcarbamylase Deficiency,&rdquo; <i>Neurology</i>, 1995, 45(3 Pt 1):593-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/7898728/pubmed\" target=\"_blank\" id=\"7898728\">7898728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15668440\"></a>Limdi NA, Shimpi AV, Faught E, et al, &ldquo;Efficacy of Rapid I.V. Administration of Valproic Acid for Status Epilepticus,&rdquo; <i>Neurology</i>, 2005, 64(2):353-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/15668440/pubmed\" target=\"_blank\" id=\"15668440\">15668440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Limdi NA, Knowlton RK, Cofield SS, et al, &ldquo;Safety of Rapid Intravenous Loading of Valproate,&rdquo; <i>Epilepsia</i>, 2007, 48(3):478-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/17319914/pubmed\" target=\"_blank\" id=\"17319914\">17319914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meador KJ, Baker GA, Browning N, et al, &ldquo;Cognitive Function at 3 Years of Age After Fetal Exposure to Antiepileptic Drugs,&rdquo; <i> N Engl J Med</i>, 2009, 360(16): 1597-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/19369666/pubmed\" target=\"_blank\" id=\"19369666\">19369666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17940245\"></a>Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. <i>J Child Neurol</i>. 2007;22(10):1191-1197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/17940245/pubmed\" target=\"_blank\" id=\"17940245\">17940245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16864836\"></a>Misra UK, Kalita J, and Patel R, &quot;Sodium Valproate vs Phenytoin in Status Epilepticus: A Pilot Study,&quot; <i>Neurology</i>, 2006; 67(2):340-342.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/16864836/pubmed\" target=\"_blank\" id=\"16864836\">16864836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17419829\"></a>Olsen KB, Taub&oslash;ll E, and Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. <i>Acta Neurol Scand Suppl</i>. 2007;187:51-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/17419829/pubmed\" target=\"_blank\" id=\"17419829\">17419829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i>. 2008;49(7):1239-1276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/18397299/pubmed\" target=\"_blank\" id=\"18397299\">18397299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15797350\"></a>Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus&mdash;experience in 102 adult patients. <i>Seizure</i>. 2005;14(3):164-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/15797350/pubmed\" target=\"_blank\" id=\"15797350\">15797350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26797170\"></a>Plantier D, Luaut&eacute; J; SOFMER group. Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice. <i>Ann Phys Rehabil Med</i>. 2016;59(1):42-57. 10.1016/j.rehab.2015.10.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/26797170/pubmed\" target=\"_blank\" id=\"26797170\">26797170</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pratt CE and Davis SM, &ldquo;Divalproex Sodium Therapy in Elderly With Dementia-Related Agitation,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(10):1625-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/12243614/pubmed\" target=\"_blank\" id=\"12243614\">12243614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsay RE, Cantrell D, Collins SD, et al, &quot;Safety and Tolerance of Rapidly Infused Depacon: A Randomized Trial in Subjects With Epilepsy,&quot; <i>Epilepsy Res</i>, 2003; 52(3):189-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/12536052/pubmed\" target=\"_blank\" id=\"12536052\">12536052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed RC and Dutta S. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? <i>Ther Drug Monit</i>. 2006;28(3):413-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/16778728/pubmed\" target=\"_blank\" id=\"16778728\">16778728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson D, Langer A, Casso D, et al, &ldquo;Pancytopenia and Valproic Acid - A Possible Association,&rdquo; <i>J Am Geriatr Soc</i>, 1995, 43(2):198.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10980746\"></a>Sinha S and Naritoku DK, &ldquo;Intravenous Valproate is Well Tolerated in Unstable Patients With Status Epilepticus,&rdquo; <i>Neurology</i>, 2000, 55(5):722-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10980746/pubmed\" target=\"_blank\" id=\"10980746\">10980746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sink KM, Holden KF, and Yaffe K, &ldquo;Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia. A Review of Evidence,&rdquo; <i>JAMA</i>, 2005, 293(5):596-608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/15687315/pubmed\" target=\"_blank\" id=\"15687315\">15687315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. <i>J Crit Care. </i>2016;36:116-124. doi: 10.1016/j.jcrc.2016.06.023.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/27546759/pubmed\" target=\"_blank\" id=\"27546759\">27546759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snead OC 3rd and Miles MV, &ldquo;Treatment of Status Epilepticus in Children With Rectal Sodium Valproate,&quot; <i>J Pediatr,</i> 1985, 106(2):323-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/3918159 /pubmed\" target=\"_blank\" id=\"3918159 \">3918159 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. <i>J Pediatr</i>. 1997;130(6):1001-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/9202628/pubmed\" target=\"_blank\" id=\"9202628\">9202628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stavzor (valproic acid) [prescribing information]. Miami, FL: Noven Therapeutics LCC; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo; <i>J Clin Psychiatry</i>, 2005, 66(7):870-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/16013903/pubmed\" target=\"_blank\" id=\"16013903\">16013903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tariot PN, Raman R, Jakimovich L, et al, &ldquo;Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation: A Randomized, Controlled Trial,&rdquo; <i>Am J Geriatr Psychiatry</i>, 2005, 13(11):942-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/16286437/pubmed\" target=\"_blank\" id=\"16286437\">16286437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10507380\"></a>Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. <i>J Neurosurg</i>. 1999;91(4):593-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10507380/pubmed\" target=\"_blank\" id=\"10507380\">10507380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tohen M, Castillo J, Baldessarini RJ, et al, &ldquo;Blood Dyscrasias With Carbamazepine and Valproate: A Pharmacoepidemiological Study of 2,228 Patients at Risk,&rdquo; <i>Am J Psychiatry</i>, 1995, 152(3):413-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/7864268/pubmed\" target=\"_blank\" id=\"7864268\">7864268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24806973\"></a>Trinka E, H&ouml;fler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. <i>CNS Drugs</i>. 2014;28(7):623-639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/24806973/pubmed\" target=\"_blank\" id=\"24806973\">24806973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20034814\"></a>Tripathi M, Vibha D, Choudhary N, et al. Management of refractory status epilepticus at a tertiary care centre in a developing country. <i>Seizure</i>. 2010;19(2):109&ndash;111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/20034814/pubmed\" target=\"_blank\" id=\"20034814\">20034814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uberall MA, Trollmann R, Wunsiedler U, et al, &quot;Intravenous Valproate in Pediatric Epilepsy Patients With Refractory Status Epilepticus,&quot; <i>Neurology</i>, 2000, 54(11):2188-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10851397/pubmed\" target=\"_blank\" id=\"10851397\">10851397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venkataraman V and Wheless JW, &ldquo;Safety of Rapid Intravenous Infusion of Valproate Loading Doses in Epilepsy Patients,&rdquo; <i>Epilepsy Res</i>, 1999, 35(2):147-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/10372567/pubmed\" target=\"_blank\" id=\"10372567\">10372567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17020483\"></a>Warden DL, Gordon B, McAllister TW, et al; Neurobehavioral Guidelines Working Group. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. <i>J Neurotrauma</i>. 2006;23(10):1468-1501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/17020483/pubmed\" target=\"_blank\" id=\"17020483\">17020483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheless JW, Vazquez BR, Kanner AM, et al, &ldquo;Rapid Infusion With Valproate Sodium is Well Tolerated in Patients With Epilepsy,&rdquo; <i>Neurology</i>, 2004, 63(8):1507-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-drug-information/abstract-text/15505177/pubmed\" target=\"_blank\" id=\"15505177\">15505177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10035 Version 244.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708868\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F233020\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233021\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F233068\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F233025\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F233045\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F233026\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F233027\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F233028\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232991\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F232975\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22782778\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49367109\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49367104\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F16335927\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F232995\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133423\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F232994\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25497638\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F233076\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232982\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232998\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232979\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F233062\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15578418\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F233015\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232987\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233002\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F233003\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F232989\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F232992\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232978\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F232997\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570489\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233005\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10035|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=valproate-patient-drug-information\" class=\"drug drug_patient\">Valproate: Patient drug information</a></li><li><a href=\"topic.htm?path=valproate-pediatric-drug-information\" class=\"drug drug_pediatric\">Valproate: Pediatric drug information</a></li></ul></div></div>","javascript":null}